The authors observed that sex-specific differences in endogenous levels of Activin A contribute to sex dimorphisms in PDAC-induced cachexia, as well as the differential outcomes of ACVR2B-Fc treatment in attenuating tumor-induced Activin (Zhong et al., 2022). The gene discussed is ACVR2B; the disease is neoplasm.